Supranuclear Palsy, Progressive
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
Drugs by status
Phase 4 trials (3)
Phase 3 trials (9)
Phase 2 trials (18)
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (19)
- AbbVie
- Bristol-Myers Squibb
- Westat
- National Institute of Neurological Disorders and Stroke (NINDS)
- Cornell University
- German Parkinson Study Group (GPS)
- Institut National de la Santé Et de la Recherche Médicale, France
- Loma Linda University
- University of Milan
- University of Nantes
- Bankura Sammilani Medical College
- University of Tuebingen
- Philipps University of Marburg
- Lundbeck
- Pitzer Stiftung
- MSE Pharmazeutika GmbH
- The Cleveland Clinic
- AlzProtect SAS
- NeuroTau, Inc.
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (4)